[{"id":"b9b3c98f-442f-420e-95b1-8288635e2a0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04189211","created_at":"2021-01-18T20:25:11.546Z","updated_at":"2024-07-02T16:36:52.828Z","phase":"Phase 1","brief_title":"A Clinical Trial of BAT8001 on Safety, Tolerability and Pharmacokinetics for Patients","source_id_and_acronym":"NCT04189211","lead_sponsor":"Bio-Thera Solutions","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BAT8001"],"overall_status":"Unknown status","enrollment":" Enrollment 30","initiation":"Initiation: 03/07/2017","start_date":" 03/07/2017","primary_txt":" Primary completion: 12/31/2019","primary_completion_date":" 12/31/2019","study_txt":" Completion: 12/31/2020","study_completion_date":" 12/31/2020","last_update_posted":"2019-12-06"},{"id":"396482e5-e7f9-4fdf-aca1-26aeff2d2d41","acronym":"","url":"https://clinicaltrials.gov/study/NCT04185649","created_at":"2021-01-18T20:24:12.804Z","updated_at":"2024-07-02T16:36:52.943Z","phase":"Phase 3","brief_title":"The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer","source_id_and_acronym":"NCT04185649","lead_sponsor":"Bio-Thera Solutions","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lapatinib • capecitabine • BAT8001"],"overall_status":"Unknown status","enrollment":" Enrollment 410","initiation":"Initiation: 07/01/2018","start_date":" 07/01/2018","primary_txt":" Primary completion: 07/31/2020","primary_completion_date":" 07/31/2020","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2019-12-04"},{"id":"7314ecf5-b124-470d-afc2-8ef412282820","acronym":"","url":"https://clinicaltrials.gov/study/NCT04151329","created_at":"2021-01-18T20:15:54.970Z","updated_at":"2024-07-02T16:36:53.955Z","phase":"Phase 1/2","brief_title":"A Phase I Clinical Trial of BAT1306 and BAT8001 Injection in Patients With Solid Tumor","source_id_and_acronym":"NCT04151329","lead_sponsor":"Bio-Thera Solutions","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BAT8001 • BAT1306"],"overall_status":"Unknown status","enrollment":" Enrollment 72","initiation":"Initiation: 06/21/2019","start_date":" 06/21/2019","primary_txt":" Primary completion: 12/31/2020","primary_completion_date":" 12/31/2020","study_txt":" Completion: 06/30/2021","study_completion_date":" 06/30/2021","last_update_posted":"2019-11-05"}]